WALTHAM, Mass., Oct. 27, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported positive interim results from an ongoing phase 2 study of ZYBRESTAT in patients with platinum-resistant ovarian cancer. Ten of 34 evaluable patients (29%) enrolled to date in the ongoing, single-arm, Simon two-stage design study evaluating the combination of ZYBRESTAT and chemotherapy (carboplatin and paclitaxel) had partial responses as measured by tumor imaging (RECIST) and/or ovarian cancer biomarker (CA-125) criteria. An additional unconfirmed partial response was observed in a patient lost to follow up, and stable disease responses were observed in an additional nine patients. The combination regimen of ZYBRESTAT and chemotherapy was observed to be well tolerated.
